Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer
Abstract Background Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified. Methods After 1 year of cetuximab treatment, patients were divided into an effective group and an ineffective group. The interleukin‐3...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Wiley
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/a90dc28a276847e28e408e853d44edcc |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|